Skip to main content

Main menu

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • Early View
  • Archive
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • COVID-19 submission information
    • Institutional open access agreements
    • Peer reviewer login
  • Alerts
  • Subscriptions

Short-term effects of menthol on walking dyspnoea in patients with COPD: a randomised, single blinded, cross-over study

Guillaume Prieur, Marc Beaumont, Mathieu Delorme, Yann Combret, Clement Medrinal, Roger Hilfiker, Tristan Bonnevie, Francis-Edouard Gravier, Pauline Smondack, Bouchra Lamia, Gregory Reychler
ERJ Open Research 2021 7: 00450-2021; DOI: 10.1183/23120541.00450-2021
Guillaume Prieur
1Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL and Dermatologie, Groupe de Recherche en Kinésithérapie Respiratoire, Université Catholique de Louvain, Brussels, Belgium
2Normandie Univ, UNIROUEN, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
3Groupe Hospitalier du Havre, Pulmonology Dept and Pulmonary Rehabilitation Dept, Montivilliers, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: gprieur.kine@gmail.com
Marc Beaumont
4Pulmonary Rehabilitation Dept, CH des Pays de Morlaix, Kersaint Gilly, Morlaix, France
5EA3878 (GETBO) CIC INSERM 1412, European University of Occidental Brittany, Brest, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathieu Delorme
6Université Paris-Saclay, UVSQ, ERPHAN, Versailles, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mathieu Delorme
Yann Combret
1Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL and Dermatologie, Groupe de Recherche en Kinésithérapie Respiratoire, Université Catholique de Louvain, Brussels, Belgium
3Groupe Hospitalier du Havre, Pulmonology Dept and Pulmonary Rehabilitation Dept, Montivilliers, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yann Combret
Clement Medrinal
3Groupe Hospitalier du Havre, Pulmonology Dept and Pulmonary Rehabilitation Dept, Montivilliers, France
6Université Paris-Saclay, UVSQ, ERPHAN, Versailles, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roger Hilfiker
7University of Applied Sciences and Arts Western Switzerland Valais (HES-SO Valais-Wallis), Physiotherapy, Sierre, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Roger Hilfiker
Tristan Bonnevie
2Normandie Univ, UNIROUEN, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
8ADIR Association, Rouen University Hospital, Rouen, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tristan Bonnevie
Francis-Edouard Gravier
2Normandie Univ, UNIROUEN, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
8ADIR Association, Rouen University Hospital, Rouen, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francis-Edouard Gravier
Pauline Smondack
8ADIR Association, Rouen University Hospital, Rouen, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bouchra Lamia
2Normandie Univ, UNIROUEN, EA3830-GRHV, Institute for Research and Innovation in Biomedicine (IRIB), Rouen, France
3Groupe Hospitalier du Havre, Pulmonology Dept and Pulmonary Rehabilitation Dept, Montivilliers, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gregory Reychler
1Institut de Recherche Expérimentale et Clinique (IREC), Pôle de Pneumologie, ORL and Dermatologie, Groupe de Recherche en Kinésithérapie Respiratoire, Université Catholique de Louvain, Brussels, Belgium
9Service de Pneumologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Gregory Reychler
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Chewing menthol gum prior to exercise is a safe, easy-to-implement, low-cost, non-pharmacologic intervention that provides a reduction in dyspnoea in a third of patients and decreases the perception of discomfort during exercise in two-thirds of patients https://bit.ly/3FoFHp1

To the Editor:

Exertional respiratory discomfort is the most common symptom in patients with COPD [1]. Menthol has recently been proposed as an ergogenic aid to decrease the perception of dyspnoea during exercise [2–4]. Menthol activates the transient receptor potential melastatin 8 (TRPM8) channels in the sensory nerve fibres of the tongue, promoting a feeling of freshness and a cognitive illusion of airflow into the airways [2, 5, 6]. We hypothesised that chewing menthol-flavoured gum before exercise would decrease the perception of dyspnoea during walking in COPD patients.

We conducted a randomised, cross-over, multicentre trial (Groupe Hospitalier du Havre, center hospitalier de Morlaix, center Resp'Air Talence) (ClinicalTrials.gov identifier: NCT03626519). Inclusion criteria were diagnosis of COPD (per Global Initiative for Chronic Obstructive Lung Disease guidelines), participation in a pulmonary rehabilitation programme, functional dyspnoea (modified Medical Research Council (mMRC) scale ≥2) and consent to participate. Exclusion criteria were clinical instability (pH <7.35 or body temperature >38°C), neurological/orthopaedic disorders, difficulty with chewing and swallowing disorders.

Participants performed the 6-min walk test (6MWT) once during the baseline assessment for familiarisation. On the test day (between 2 and 5 days after the baseline assessment), they performed two 6MWT, separated by 30 min of rest, in two different, randomised conditions. In the experimental condition, participants chewed menthol-flavoured gum (Airwaves Extreme Menthol Extreme, Wrigley, Chicago, IL, USA) for 5 min before the test and in the control condition, they chewed strawberry-flavoured gum (Hollywood Strawberry Style, Mondelēz International, Uxbridge, UK). No encouragement was given during the 6MWT to avoid influencing participants.

The primary outcome was end-of-task dyspnoea measured using the modified 0–10 Borg scale (0=no dyspnoea, 10=maximal dyspnoea).

Secondary outcomes were end-of-task leg discomfort (0–10 Borg scale), peripheral oxygen saturation, heart rate, tidal volume, minute ventilation, inspiratory capacity and respiratory rate (measured using Spirodoc (Medical International Research, Rome, Italy)), and 6-min walking distance. After completion of both tests, participants were asked which condition they had preferred and if they felt that the menthol had had any effect.

A randomisation sequence was determined for each centre by the research unit using Edgar2 (www.Edgarweb.Org.Uk/) computer software (ratio 1:1). The randomised condition sequence was provided in a closed, opaque envelope with the patient's inclusion number on the front and opened by a research assistant just before the first condition. Participants could not be blinded; however, their knowledge of the purpose of the study was limited to “the impact of menthol on effort”. Assessors were blinded to the condition. This was ensured by: 1) the participant chewing the gum in a closed room while the assessor waited at the test site; and 2) the assessor remaining at a minimum distance of 2 m from the participant to avoid smelling their breath. 63 participants were required to detect a between conditions difference of 1 point on the modified Borg scale 0–10 (minimal clinically important difference) [7] and a moderate effect size (0.5) on end-of-task dyspnoea with a power of 80% and an alpha risk ≤0.05.

Mean differences were calculated using a mixed model adjusted for baseline values, and the sequence (order of conditions) was used to assess the carry-over effect, with participants as random effects. R-software was used (https://www.R-project.org/) with the packages lme4 and lmerTest [8–10]). Statistical analysis was performed blind.

This study was approved by the French Ethics committee Sud-Est 6 (17 May 2018). Written informed consent was obtained from all patients.

63 patients were included between October 2019 and February 2021 (male/female ratio: 38/25, mean±sd age: 68±20 years and mean±sd body mass index: 27±7 kg·m−2). Patients had severe bronchial obstruction (mean±sd forced expiratory volume in 1 s (FEV1): 44±15% predicted; mean±sd forced vital capacity: 76±18% predicted) and lung hyperinflation (mean±sd residual volume: 166±50% predicted; mean±sd total lung capacity: 110±19% predicted; mean±sd inspiratory capacity: 77±23% predicted). All participants had functional dyspnoea (mean±sd mMRC 2.4±0.6) and their COPD significantly impacted on their performance of activities of daily living (St George's Respiratory Questionnaire – activities limitations mean±sd 68±20%; scores range from 0 to 100, higher scores indicate more severe limitations).

A trend towards reduced dyspnoea with menthol was observed, but the benefits were trivial (table 1). The lower bound of the confidence interval did not reach the minimal clinically important difference of 1 point on the modified Borg scale [11]. However, analysis of individual data showed that the menthol reduced dyspnoea by at least 1 point in 21 participants (33%). 40 participants (63%) reported a positive effect of the menthol on their exercise tolerance. Only two participants reported having worse dyspnoea in the menthol condition. No between condition differences were observed for the secondary outcomes (table 1). For leg discomfort, there was evidence of a period or cross-over effect (p=0.050), this result should therefore be interpreted with caution. There was no evidence of a period or carry-over effect for any of the other outcomes. No baseline characteristic identified responder patients; however, the confidence interval showed a trend that patients with FEV1 <35% predicted were more likely to respond (relative risk 1.67 (95% CI 0.87–3.21) p=0.16).

View this table:
  • View inline
  • View popup
TABLE 1

Effects of menthol gum versus control gum on dyspnoea and physiological variables at the end of exercise

Cooling sensations have previously been shown to reduce dyspnoea. For example, breathing fresh air (7°C) modestly decreased dyspnoea and increased peak exercise performance in patients with COPD [12]. Menthol can provide a cooling sensation by stimulating the membrane bound ion channel, TRPM8, inducing a perceived reduction in temperature within the range of 8–28°C [4]. This cooling sensation could increase the cognitive inspiratory flow and may alter the emotional and affective perception of dyspnoea [2].

The results of the present study showed a clinically trivial effect of menthol on end-test dyspnoea compared with the control condition; however, the reduction in dyspnoea reached the minimal clinically important difference in one-third of the participants and two-thirds reported a positive effect on their exercise tolerance.

We propose two explanations for this small effect. First, the Borg scale may not be sufficiently sensitive to detect a between-condition difference. The study by Kanezaki et al. [2] found a reduction in physical and mental breathing effort, air hunger, breathing discomfort, anxiety, and fear during inspiratory resistive loaded breathing in patients with COPD following olfactive stimulation by L-menthol using the Multidimensional Dyspnea Profile scale. This reflects the self-reported perception of the patients in our study. Secondly, individuals often modify their level of exertion during self-paced exercise tests, based on their level of dyspnoea. This could also explain why other studies failed to show a benefit of non-pharmacological strategies on exertional dyspnoea using the 6MWT [13, 14]. High-intensity constant work rate endurance tests are more sensitive for the detection of the effectiveness of an intervention [3, 15, 16].

Although no carry-over effect of menthol was observed on dyspnoea, we do not know the duration of the effect of menthol and its potential impact on the next condition is not known. Future studies could perhaps include a washout period longer than 30 min between the two conditions.

Another explanation for the negative result is that the sensation of breathing comfort faded over the course of the test as the menthol effect dissipated: several participants reported that they mainly felt the benefit during the first few minutes of the test. Studies in athletes reported a stronger effect of repeated menthol use on dyspnoea and on performance [4]. The lack of an effect on ventilatory pattern is in line with the results of Kanezaki et al. [2].

This study addressed a new area of research, looking at alternative and pragmatic approaches to the management of breathlessness. Future studies should take the methodological limitations that we outlined into consideration to optimise future studies in this field.

This multicentre study has several strengths: the assessors were blinded to limit measurement bias and the instructions given to patients were standardised to limit a centre effect. Patients were unaware that the primary outcome was dyspnoea to minimise the influence on this outcome. We asked patients to be as honest as possible about how they felt about menthol, and to report both positive and negative aspects.

Chewing menthol gum prior to exercise is a safe, easy-to-implement, low-cost, non-pharmacological intervention that provides a clinically important reduction in dyspnoea in one third of patients and decreases the perception of discomfort during exercise in two-thirds of patients. Continuous release or repeated administration of menthol may have a greater effect on dyspnoea reduction throughout exercise [4].

Acknowledgements

We thank Johanna Robertson (self-employed translator, Nantes, France) for translation and constructive criticism.

Footnotes

  • Provenance: Submitted article, peer reviewed.

  • This study is registered at www.ClinicalTrials.gov with identifier number NCT03626519. All of the anonymised individual participant data collected during the trial are available (no end date). Requests should be directed to gprieur.kine@gmail.com.

  • Conflict of interest: G. Prieur has nothing to disclose.

  • Conflict of interest: M. Beaumont has nothing to disclose.

  • Conflict of interest: M. Delorme has nothing to disclose.

  • Conflict of interest: Y. Combret has nothing to disclose.

  • Conflict of interest: C. Medrinal has nothing to disclose.

  • Conflict of interest: R. Hilfiker has nothing to disclose.

  • Conflict of interest: T. Bonnevie has nothing to disclose.

  • Conflict of interest: F-E. Gravier has nothing to disclose.

  • Conflict of interest: P. Smondack has nothing to disclose.

  • Conflict of interest: B. Lamia has nothing to disclose.

  • Conflict of interest: G. Reychler has nothing to disclose.

  • Support statement: This work was supported by GHAHR Association (Le Havre, France).

  • Received July 6, 2021.
  • Accepted August 19, 2021.
  • Copyright ©The authors 2021
http://creativecommons.org/licenses/by-nc/4.0/

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions{at}ersnet.org

References

  1. ↵
    1. Nishimura K,
    2. Izumi T,
    3. Tsukino M, et al.
    Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002; 121: 1434–1440. doi:10.1378/chest.121.5.1434
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kanezaki M,
    2. Terada K,
    3. Ebihara S
    . Effect of olfactory stimulation by L-menthol on laboratory-induced dyspnea in COPD. Chest 2020; 157: 1455–1465. doi:10.1016/j.chest.2019.12.028
    OpenUrl
  3. ↵
    1. Kanezaki M,
    2. Ebihara S
    . Effect of the cooling sensation induced by olfactory stimulation by L-menthol on dyspnoea: a pilot study. Eur Respir J 2017; 49: 1601823. doi:10.1183/13993003.01823-2016
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Barwood MJ,
    2. Gibson OR,
    3. Gillis DJ, et al.
    Menthol as an ergogenic aid for the Tokyo 2021 Olympic Games: an expert-led consensus statement using the modified Delphi method. Sports Med 2020; 50: 1709–1727. doi:10.1007/s40279-020-01313-9
    OpenUrlPubMed
  5. ↵
    1. Peier AM,
    2. Moqrich A,
    3. Hergarden AC, et al.
    A TRP channel that senses cold stimuli and menthol. Cell 2002; 108: 705–715. doi:10.1016/S0092-8674(02)00652-9
    OpenUrlCrossRefPubMed
  6. ↵
    1. McKemy DD,
    2. Neuhausser WM,
    3. Julius D
    . Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 2002; 416: 52–58. doi:10.1038/nature719
    OpenUrlCrossRefPubMed
  7. ↵
    1. Ries AL
    . Minimally clinically important difference for the UCSD shortness of breath questionnaire, Borg scale, and visual analog scale. COPD: J Chron Obstruct Pulmon Dis 2005; 2: 105–110. doi:10.1081/COPD-200050655
    OpenUrl
  8. ↵
    1. Senn S
    . Cross-over Trials in Clinical Research. 2nd Edn. New York, J. Wiley, 2002.
    1. Bates D,
    2. Mächler M,
    3. Bolker B, et al.
    Fitting linear mixed-effects models using lme4. J Stat Soft 2015; 67: 1–48. doi:10.18637/jss.v067.i01
    OpenUrl
  9. ↵
    1. Kuznetsova A,
    2. Brockhoff PB,
    3. Christensen RHB
    . lmerTest package: tests in linear mixed effects models. J Stat Soft 2017; 82: 1–26. Doi:10.18637/jss.v082.i13
    OpenUrlCrossRef
  10. ↵
    1. Jones PW,
    2. Beeh KM,
    3. Chapman KR, et al.
    Minimal clinically important differences in pharmacological trials. Am J Respir Crit Care Med 2014; 189: 250–255. doi:10.1164/rccm.201310-1863PP
    OpenUrlCrossRefPubMed
  11. ↵
    1. Spence DPS,
    2. Graham DR,
    3. Ahmed J, et al.
    Does cold air affect exercise capacity and dyspnea in stable chronic obstructive pulmonary disease? Chest 1993; 103: 693–696. doi:10.1378/chest.103.3.693
    OpenUrlCrossRefPubMed
  12. ↵
    1. Pfister T,
    2. Berrol C,
    3. Caplan C
    . Effects of music on exercise and perceived symptoms in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 1998; 18: 228–232. doi:10.1097/00008483-199805000-00007
    OpenUrlCrossRefPubMed
  13. ↵
    1. Caty G,
    2. Pieters T,
    3. Liistro G, et al.
    Influence of music with a fast tempo on the 6-minute walk test in copd patients. Ann Phys Rehabil Med 2013; 56: e327. doi:10.1016/j.rehab.2013.06.003
    OpenUrl
  14. ↵
    1. Lee AL,
    2. Dolmage TE,
    3. Rhim M, et al.
    The impact of listening to music during a high-intensity exercise endurance test in people with COPD. Chest 2018; 153: 1134–1141. doi:10.1016/j.chest.2017.12.001
    OpenUrl
  15. ↵
    1. Borel B,
    2. Provencher S,
    3. Saey D, et al.
    Responsiveness of various exercise-testing protocols to therapeutic interventions in COPD. Pulm Med 2013; 2013: 410748. doi:10.1155/2013/410748
    OpenUrlPubMed
PreviousNext
Back to top
Vol 7 Issue 4 Table of Contents
ERJ Open Research: 7 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Short-term effects of menthol on walking dyspnoea in patients with COPD: a randomised, single blinded, cross-over study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Short-term effects of menthol on walking dyspnoea in patients with COPD: a randomised, single blinded, cross-over study
Guillaume Prieur, Marc Beaumont, Mathieu Delorme, Yann Combret, Clement Medrinal, Roger Hilfiker, Tristan Bonnevie, Francis-Edouard Gravier, Pauline Smondack, Bouchra Lamia, Gregory Reychler
ERJ Open Research Oct 2021, 7 (4) 00450-2021; DOI: 10.1183/23120541.00450-2021

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Short-term effects of menthol on walking dyspnoea in patients with COPD: a randomised, single blinded, cross-over study
Guillaume Prieur, Marc Beaumont, Mathieu Delorme, Yann Combret, Clement Medrinal, Roger Hilfiker, Tristan Bonnevie, Francis-Edouard Gravier, Pauline Smondack, Bouchra Lamia, Gregory Reychler
ERJ Open Research Oct 2021, 7 (4) 00450-2021; DOI: 10.1183/23120541.00450-2021
Reddit logo Technorati logo Twitter logo Connotea logo Facebook logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Pulmonary pharmacology and therapeutics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • A 3D-engineered silicone stent
  • Obesity does not modify effect of CPAP on insulin resistance
  • Asthma prevalence and medication dispensation
Show more Research letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About ERJ Open Research

  • Editorial board
  • Journal information
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Online ISSN: 2312-0541

Copyright © 2023 by the European Respiratory Society